Acrux Limited (ACR.AX)
AUD 0.02
(4.55%)
AUD 0.02
(4.55%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 5.09 Million AUD | -39.6% |
| 2023 | 8.42 Million AUD | 390.34% |
| 2022 | 1.71 Million AUD | 28.57% |
| 2021 | 1.33 Million AUD | 6.7% |
| 2020 | 1.25 Million AUD | 98.57% |
| 2019 | 631 Thousand AUD | -81.61% |
| 2018 | 3.43 Million AUD | -85.66% |
| 2017 | 23.93 Million AUD | -16.19% |
| 2016 | 28.55 Million AUD | 12.57% |
| 2015 | 25.36 Million AUD | -52.9% |
| 2014 | 53.85 Million AUD | 246.38% |
| 2013 | 15.54 Million AUD | 76.75% |
| 2012 | 8.79 Million AUD | -90.18% |
| 2011 | 89.6 Million AUD | 63.2% |
| 2010 | 54.9 Million AUD | 8346.77% |
| 2009 | 650 Thousand AUD | -83.08% |
| 2008 | 3.84 Million AUD | 32.59% |
| 2007 | 2.89 Million AUD | 460.35% |
| 2006 | 517 Thousand AUD | -80.93% |
| 2005 | 2.71 Million AUD | -16.96% |
| 2004 | 3.26 Million AUD | 337.46% |
| 2003 | 746.3 Thousand AUD | 36.33% |
| 2002 | 547.44 Thousand AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 4.4 Million AUD | 0.0% |
| 2024 FY | 5.09 Million AUD | -39.6% |
| 2024 Q4 | 682 Thousand AUD | 0.0% |
| 2023 FY | 8.42 Million AUD | 390.34% |
| 2023 Q2 | 1.42 Million AUD | 0.0% |
| 2023 Q4 | 7 Million AUD | 0.0% |
| 2022 Q4 | 1.01 Million AUD | 0.0% |
| 2022 Q2 | 702 Thousand AUD | 0.0% |
| 2022 FY | 1.71 Million AUD | 28.57% |
| 2021 Q2 | 788 Thousand AUD | 0.0% |
| 2021 Q4 | 549 Thousand AUD | 0.0% |
| 2021 FY | 1.33 Million AUD | 6.7% |
| 2020 FY | 1.25 Million AUD | 98.57% |
| 2020 Q4 | 817 Thousand AUD | 0.0% |
| 2020 Q2 | 436 Thousand AUD | 0.0% |
| 2019 Q2 | 2.33 Million AUD | 0.0% |
| 2019 Q4 | 356 Thousand AUD | 0.0% |
| 2019 FY | 631 Thousand AUD | -81.61% |
| 2018 Q2 | 2.42 Million AUD | 0.0% |
| 2018 FY | 3.43 Million AUD | -85.66% |
| 2018 Q4 | 1.01 Million AUD | 0.0% |
| 2017 Q2 | 14.02 Million AUD | 0.0% |
| 2017 FY | 23.93 Million AUD | -16.19% |
| 2017 Q4 | 9.9 Million AUD | 0.0% |
| 2016 FY | 28.55 Million AUD | 12.57% |
| 2016 Q2 | 17.76 Million AUD | 0.0% |
| 2016 Q4 | 10.79 Million AUD | 0.0% |
| 2015 Q2 | 13.9 Million AUD | 0.0% |
| 2015 Q4 | 11.46 Million AUD | 0.0% |
| 2015 FY | 25.36 Million AUD | -52.9% |
| 2014 FY | 53.85 Million AUD | 246.38% |
| 2014 Q4 | 10.45 Million AUD | 0.0% |
| 2014 Q2 | 43.4 Million AUD | 0.0% |
| 2013 FY | 15.54 Million AUD | 76.75% |
| 2013 Q4 | 11.96 Million AUD | 0.0% |
| 2013 Q2 | 4.56 Million AUD | 0.0% |
| 2012 Q3 | 2.19 Million AUD | 0.0% |
| 2012 FY | 8.79 Million AUD | -90.18% |
| 2012 Q2 | 2.19 Million AUD | -90.18% |
| 2012 Q1 | 22.4 Million AUD | 0.0% |
| 2012 Q4 | - AUD | -100.0% |
| 2011 Q4 | - AUD | -100.0% |
| 2011 FY | 89.6 Million AUD | 63.2% |
| 2011 Q1 | 13.72 Million AUD | 0.0% |
| 2011 Q2 | 22.4 Million AUD | 63.2% |
| 2011 Q3 | 22.4 Million AUD | 0.0% |
| 2010 Q4 | - AUD | -100.0% |
| 2010 Q1 | 162.5 Thousand AUD | 0.0% |
| 2010 Q2 | 13.72 Million AUD | 8346.77% |
| 2010 Q3 | 13.72 Million AUD | 0.0% |
| 2010 FY | 54.9 Million AUD | 8346.77% |
| 2009 Q1 | 1.12 Million AUD | 0.0% |
| 2009 FY | 650 Thousand AUD | -83.08% |
| 2009 Q2 | 162.5 Thousand AUD | -85.54% |
| 2009 Q4 | - AUD | -100.0% |
| 2009 Q3 | 162.5 Thousand AUD | 0.0% |
| 2008 Q4 | - AUD | -100.0% |
| 2008 Q2 | 1.12 Million AUD | 55.2% |
| 2008 Q1 | 724.25 Thousand AUD | 0.0% |
| 2008 FY | 3.84 Million AUD | 32.59% |
| 2008 Q3 | 1.12 Million AUD | 0.0% |
| 2007 Q4 | - AUD | -100.0% |
| 2007 Q2 | 724.25 Thousand AUD | 460.35% |
| 2007 Q1 | 129.25 Thousand AUD | 0.0% |
| 2007 Q3 | 724.25 Thousand AUD | 0.0% |
| 2007 FY | 2.89 Million AUD | 460.35% |
| 2006 Q1 | 677.77 Thousand AUD | 0.0% |
| 2006 Q4 | - AUD | -100.0% |
| 2006 Q3 | 129.25 Thousand AUD | 0.0% |
| 2006 FY | 517 Thousand AUD | -80.93% |
| 2006 Q2 | 129.25 Thousand AUD | -80.93% |
| 2005 Q3 | 677.77 Thousand AUD | 0.0% |
| 2005 Q4 | - AUD | -100.0% |
| 2005 FY | 2.71 Million AUD | -16.96% |
| 2005 Q1 | 816.2 Thousand AUD | 0.0% |
| 2005 Q2 | 677.77 Thousand AUD | -16.96% |
| 2004 Q2 | 816.2 Thousand AUD | 337.46% |
| 2004 Q3 | 816.2 Thousand AUD | 0.0% |
| 2004 Q4 | - AUD | -100.0% |
| 2004 FY | 3.26 Million AUD | 337.46% |
| 2004 Q1 | 186.57 Thousand AUD | 0.0% |
| 2003 Q4 | 186.57 Thousand AUD | 0.0% |
| 2003 FY | 746.3 Thousand AUD | 36.33% |
| 2003 Q2 | 186.57 Thousand AUD | 36.33% |
| 2003 Q3 | 186.57 Thousand AUD | 0.0% |
| 2003 Q1 | 136.86 Thousand AUD | 0.0% |
| 2002 Q3 | 136.86 Thousand AUD | 0.0% |
| 2002 Q2 | 136.86 Thousand AUD | 0.0% |
| 2002 Q4 | 136.86 Thousand AUD | 0.0% |
| 2002 FY | 547.44 Thousand AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AdAlta Limited | 1.73 Million AUD | -192.957% |
| Actinogen Medical Limited | 9.93 Million AUD | 48.739% |
| AnteoTech Limited | 460.39 Thousand AUD | -1005.785% |
| Argenica Therapeutics Limited | 2.59 Million AUD | -95.963% |
| Arovella Therapeutics Limited | 17 Thousand AUD | -29847.059% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Alterity Therapeutics Limited | 4.01 Million AUD | -26.664% |
| Amplia Therapeutics Limited | 4.45 Million AUD | -14.334% |
| Avecho Biotechnology Limited | 473.55 Thousand AUD | -975.069% |
| Bio-Gene Technology Limited | 18.32 Thousand AUD | -27689.301% |
| Biome Australia Limited | 13 Million AUD | 60.865% |
| Biotron Limited | - AUD | -Infinity% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -745.934% |
| BTC Health Limited | 16.36 Thousand AUD | -31018.582% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 31.735% |
| CSL Limited | 22.41 Billion AUD | 99.977% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 55.756% |
| Clinuvel Pharmaceuticals Limited | 88.17 Million AUD | 94.226% |
| Cynata Therapeutics Limited | 2.31 Million AUD | -119.853% |
| Dimerix Limited | 583.47 Thousand AUD | -772.526% |
| EZZ Life Science Holdings Limited | 66.44 Million AUD | 92.338% |
| Hexima Limited | - AUD | -Infinity% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -306.767% |
| Immuron Limited | 4.9 Million AUD | -3.837% |
| Immutep Limited | 3.5 Million AUD | -45.22% |
| Imugene Limited | - AUD | -Infinity% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -319.961% |
| Memphasys Limited | 60 Thousand AUD | -8385.0% |
| Nanollose Limited | 12.5 Thousand AUD | -40624.742% |
| Neuren Pharmaceuticals Limited | 231.92 Million AUD | 97.805% |
| Noxopharm Limited | 2.4 Million AUD | -112.101% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Nyrada Inc. | - AUD | -Infinity% |
| Orthocell Limited | 5.31 Million AUD | 4.221% |
| PharmAust Limited | - AUD | -Infinity% |
| Patrys Limited | 1.39 Million AUD | -265.165% |
| Paradigm Biopharmaceuticals Limited | 65.8 Thousand AUD | -7637.082% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -470.648% |
| Prescient Therapeutics Limited | 3.71 Million AUD | -37.136% |
| PYC Therapeutics Limited | 22.05 Million AUD | 76.921% |
| Race Oncology Limited | 4 Million AUD | -27.165% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -1601.378% |
| Recce Pharmaceuticals Ltd | - AUD | -Infinity% |
| Starpharma Holdings Limited | 8.28 Million AUD | 38.581% |
| Telix Pharmaceuticals Limited | 496.65 Million AUD | 98.975% |
| Tissue Repair Ltd | 152.24 Thousand AUD | -3244.062% |
| Zelira Therapeutics Limited | 94.95 Thousand AUD | -5261.656% |